

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221409 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)
A61K 39/395 (2006.01) A61K 47/68 (2017.01)
A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2022/024620

(22) International Filing Date:

13 April 2022 (13.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/174,772 14 April 2021 (14.04.2021) US
63/279,762 16 November 2021 (16.11.2021) US

(71) Applicant: VILLARIS THERAPEUTICS, INC.

[US/US]; 2500 Regency Parkway, Cary, North Carolina
27518 (US).

(72) Inventors: FINLAY, William James Jonathan; 4 Cleve-

den Drive, Glasgow G12 0SE (GB). HARRIS, John E.; 6
Noahs Way, Sterling, Massachusetts 01564 (US).

(74) Agent: ELRIFI, Ivor R. et al.; 1299 Pennsylvania Ave.,

NW Suite 700, Washington, District of Columbia 20004
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CD122 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: Provided herein are antibody molecules that bind specifically to CD122 and antigen-binding portions thereof and related compositions, nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

WO 2022/221409 A1